Mark-Steven Steiner’s Post

View profile for Mark-Steven Steiner, graphic

Innovator | Mentor | Partner | Lateral Flow | Nanoparticle | Protein Chemistry Expert

As the dust settles on MEDICA 2023, it's clear that the lateral flow field is not just evolving; it's maturing with a purpose. Reflecting on an incredible week at MEDICA 2023, I feel a deep sense of gratitude for the myriad of enriching conversations and the inspiring individuals I met. The exchange of ideas and experiences in the life sciences community is always a highlight of my professional year.   Key Observations from MEDICA 2023 in the Lateral Flow Field:   🌱 Steady Development: While groundbreaking innovations were sparse, a consistent progress in technology and application is clearly visible. 📜 IVDR Feedback: The general consensus points towards the IVDR being costly, complex and slow, seen as barrier to innovation and nudging a shift towards less regulated domains like animal care and environmental testing. 🔄 Post-Pandemic Consolidation: A phase of introspection and realignment is evident, as the industry recalibrates strategies in the post-pandemic era. 🌍 Towards Sustainability: Conversations around sustainability in product development are emerging, signaling a responsible and necessary shift in our industry.   As we are part and creator of these evolving dynamics, what are your thoughts on the future of lateral flow technology? How do you see these trends shaping our approach to innovation and sustainability in the life sciences sector? Disclaimer: All images were produced using AI DALL-E

  • image, designed to represent MEDICA 2023 and the advancements in the lateral flow field
Nicolas Heureux, PhD

Scientific Solutions Manager at Kimialys | Mixing biology, chemistry and physics to push biosensing further | Passioned about antibodies, LFA, SPR and IP-MS

10mo

From our discussion before and at MEDICA, many companies are looking at how bringing Lateral Flow tests in sectors and applications where it was not possible so far. By looking at technologies to increase sensitivity, by going quantitative with readers, by simplifying and improving the usability, by connecting the results to cloud-based apps, etc.

Mitzi Rettinger

Collaborating with industry to design & develop diagnostics I DCN Dx

10mo

Thank you for sharing your observations Mark-Steven Steiner. #medica2023 was busy for me as well. Lots of great conversations with many in the #lateralflow ecosystem. I agree clinical is costly but those that can invest and create a platform including a reader (with or without an app) and a menu of assays will fill a need for #pointofcaretesting and #athomecare. I too saw lots of interest in reader technology.

Stacey Pazar Huth

Independent Consultant, Product Development | Freelancer | Advisor

10mo

Mark-Steven Steiner thank you for posting. I’m curious - any chance you could expand on the sustainability aspect? Are there examples happening now?

Mitchell Pease

Accelerating the future of precision medicines @ Sano Genetics 🧬

10mo

Commenting for my network! Great insights, thanks Steven!

Kristin Cederquist

Senior Scientist at DCN Dx, Assay Development

10mo

In addition to environmental and animal care, also seeing a big push in companies I'm finding on LinkedIn in the area of general "wellness" (the best encompassing term I can think of for it) that isn't necessarily quantitatively diagnostic, but shows trends. I remember Darren Rowles taking about plastic waste well before Covid, and now it seems with the Okos Diagnostics Gelassette and other initiatives you talked about, it's a front and center topic. Good discussion!

Fernando Ammann

Making Selling and Buying European Businesses Easy

10mo

Great article Mark-Steven Steiner, love the fact that you generate your own pictures 👍

Like
Reply
Sander Julian Brus

Connecting human and environmental health // Founder Okos Diagnostics

10mo

Great overview! Mark-Steven Steiner💡

See more comments

To view or add a comment, sign in

Explore topics